OncoPharm

Reviewing the recent Lancet publication of CASPIAN (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32222-6/fulltext) --> durvalumab + chemo in extensive stage small cell lung cancer.

Recapping updates from ESMO 2019. Topics include FLAURA (osimertinib), 5-year OS analyses of immunotherapy in metastatic NSCLC & melanoma, EGFR/BRAF/MEK inhibition in BRAF-V600E colorectal cancer, PARP inhibitors in ovarian cancer, and a possible cabazitaxel comeback.

The Landmarks in #Oncopharm series returns on the 10-year anniversary of this landmark paper (https://www.nejm.org/doi/10.1056/NEJMoa0904544) comparing daunorubicin 90 mg/m2 vs. 45 mg/m2 for AML induction.

Discussion of FDA's approval of lenvatinib & pembrolizumab for endometrial cancer followed by a comparison of TITAN v. ENZAMET prompted by apalutamide's latest approval.

Recapping the NY Times (https://www.nytimes.com/interactive/2018/10/26/magazine/netflix-diagnosis-series-joe.html) & Netflix collaboration "Diagnosis" about a possible Ibrutinib ADR. We also the discuss the value of case reports for the #OncoPharm community.

The 2nd installment of the OncoPharm Morbidity & Mortality series discussed a published case report (https://www.ncbi.nlm.nih.gov/pubmed/28782406). We discuss the approach to take when a patient experiences unexpectedly extreme toxicity and the role pharmacogenetics may play. Suggested resource: https://cpicpgx.org

Dive into the fascinating world of irinotecan, a chemotherapy drug rooted in the ancient use of camptothecin. Explore how genetic differences impact treatment outcomes and side effects. Learn about the drug's complex dosing considerations and the notorious issue of diarrhea. Discover recent innovations, like the FDA-approved liposomal formulation, and how pharmacogenetic insights are reshaping personalized cancer care.

Running through the drug information highlights of the latest approved #oncopharm agents: entrectinib and fedratinib.

This week we look at the NEJM publication earlier this month (https://www.nejm.org/doi/full/10.1056/NEJMoa1817073) of E1912. Points of discussion include IGHV mutational status, PFS vs. OS as endpoints in CLL, the benefit of rituximab in addition to ibrutinib, and ibrutinib toxicity in younger vs. older CLL patients. (Also, apologies to my APPE student for dropping this Pod *after* your journal club on this paper.)

Updates on ASCO's updated VTE guidelines with a focus on prophylaxis for ambulatory cancer patients (1:15) and VTE treatment (12:50). Pembrolizumab's latest FDA-approval is discussed (16:00), as is pexidartinib's FDA-approval (18:00), and finally a comparison of BCOP pass rates by training status (22:34).